Views & Analysis Gene editing: beyond the hype Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities.
Partner Content Partner Content Targeting Solid & Liquid Malignancies with the Same CAR Cell and Gene Therapy
News FDA knocks back Pharming's bid for wider Joenja use The FDA has turned down Pharming's bid to broaden the label of Joenja for rare immunodeficiency disorder APDS so it can be used in younger patients.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
